Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
about
Revolutionizing Alzheimer's disease and clinical trials through biomarkersA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersSuspected non-Alzheimer disease pathophysiology--concept and controversyThe relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associationsPreclinical Alzheimer disease: identification of cases at risk among cognitively intact older individualsHarmonized diagnostic criteria for Alzheimer's disease: recommendationsUshering in the study and treatment of preclinical Alzheimer diseaseThree dimensions of the amyloid hypothesis: time, space and 'wingmen'Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trialsTracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersAmyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.Amyloid burden and neural function in people at risk for Alzheimer's Disease.Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanismsAmyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.The preclinical Alzheimer cognitive composite: measuring amyloid-related declineEarly detection of Alzheimer's disease using PiB and FDG PETPART and SNAP.Molecular imaging of Alzheimer disease pathologyThe evolution of preclinical Alzheimer's disease: implications for prevention trials.Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.Emerging biomarkers in cognition.Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional studyMild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progressionPittsburgh compound B retention and progression of cognitive status--a meta-analysis.Imaging biomarkers associated with cognitive decline: a review.Are AD-Typical Regions the Convergence Point of Multiple Pathologies?Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's diseaseAmyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderlyMemory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's DiseaseA Summary Score for the Framingham Heart Study Neuropsychological Battery.Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's DiseaseAbsence of practice effects in preclinical Alzheimer's disease.Suspected non-AD pathology in mild cognitive impairment
P2860
Q26744882-9B93AFAF-5615-42E8-A451-A1B53A61234EQ26745508-37BFFE83-3168-4F68-88BE-3D6F111011B6Q26771270-89A39057-A553-4CF5-BDBE-3A63ACB5F195Q26830467-9145753E-EBC4-48CC-8715-E033AFF9E697Q26995405-5D0D13C0-FBE5-461B-A596-F33BF67D1C38Q27009157-B3E93268-5563-48EB-8ED4-313E6A3E0386Q27014791-9F78678F-D0AD-45DA-9AD1-3B09255EA016Q28082768-07CE11A3-0519-44A8-AC1A-72AEE1D432C2Q28488143-201CD920-A5B3-4196-8767-17A224EF8BFFQ29620245-F29A05F2-9A05-4909-9163-646E8857C1F3Q30303122-D9925444-1B80-4C8D-A5F0-E44693B2179FQ30981669-49F64793-3EEC-4B15-9F4A-081AA876DA8AQ33559175-2C9AC58E-F7FD-4082-B820-0B2B3E666000Q33573761-2BDC21F4-F31B-446A-9A63-EE538AFAF9F6Q33599047-00C92B94-928E-4A0C-96DA-6BC6EF99E733Q33616244-24FD754B-34BA-4BC0-94EE-B10C8B5D67FCQ33672569-20A71F88-3738-4CE9-9009-04678511063CQ33740879-25268FEF-6497-4C6D-9006-F6BF5BC0177DQ34043786-3694C3E0-8055-41B0-9536-AF6E66957BF7Q34422469-07ADEECA-C501-4FDE-AEDD-EE033CF5C082Q34483878-2FC65396-2EC0-42F1-8AA7-E153507D2FA5Q34507153-1C9AF75B-41B2-4EA9-A0AB-D65E0F52FCC9Q34651135-97F2A17D-B0B5-4071-BD5B-E3C075724035Q34849048-9E316D27-8FF5-4410-B943-97568BCB0E47Q34940642-7939B465-0C1C-43A2-8DD7-0F299B018606Q35008258-79689E91-92D9-4352-986E-C1AE438F2213Q35073049-EDEDED05-30E4-48EF-B779-4F495C965F13Q35106472-1027C5F2-AC2B-42C2-BD09-845E007A6FC8Q35115487-EA151370-D910-4357-9D8A-3DB969551AC2Q35185786-58AB190A-2DF9-4FC6-9A89-6176DFAB1617Q35216192-53EEFB96-F2BC-497B-B0DB-BCA41D280F84Q35776386-9572418E-4316-464B-B633-36E7C3628CD2Q35838385-CBAEDD42-CD12-421A-B067-030F30BA4A96Q35850701-FF1339B0-BF99-4F8C-916C-D2AD9C06E6D2Q35889053-45856122-7FC8-4E51-99D6-EB2B357C415FQ35998525-C1958DFA-80C4-4ADD-94B7-5065085A47F9Q36154820-94D8D766-0C49-4E61-BAD8-2F326C805DBCQ36252707-D49C71A5-0438-4555-82CC-E8DE1C9A6E76Q36269046-42F076BA-B2CB-4DED-9583-7BB03BD92DD6Q36271438-A535E065-B48E-45C8-B9AF-571C501E940E
P2860
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@ast
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@en
type
label
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@ast
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@en
prefLabel
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@ast
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@en
P2093
P2860
P1433
P1476
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
@en
P2093
D S Knopman
J L Gunter
M L Senjem
R C Petersen
R O Roberts
S D Weigand
P2860
P304
P356
10.1212/WNL.0B013E3182563BBE
P407
P577
2012-05-02T00:00:00Z